VPRO Stock Overview
Through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Viropro Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | 0% |
3 Year Change | 0% |
5 Year Change | -99.94% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
VPRO | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 1.9% | 0.7% |
1Y | 0% | -6.6% | 23.9% |
Return vs Industry: VPRO exceeded the US Biotechs industry which returned -7.2% over the past year.
Return vs Market: VPRO underperformed the US Market which returned 24.4% over the past year.
Price Volatility
VPRO volatility | |
---|---|
VPRO Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.0% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 18.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VPRO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VPRO's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | www.viropro.net |
Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis. It manufactures biologics drugs, including bio-similars for pre-clinical, and Phase I, II, and III clinical trials; offers its clients with supply of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products; owns three clones that include two in insulin therapy and one for cancer therapy; and provides contractual research and manufacturing services to biotech and biopharmaceutical companies.
Viropro Inc. Fundamentals Summary
VPRO fundamental statistics | |
---|---|
Market cap | US$1.27k |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs VPRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VPRO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did VPRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/07 06:50 |
End of Day Share Price | 2024/11/13 00:00 |
Earnings | N/A |
Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Viropro Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|